UNILEVER PLC (UL)
NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-10-23
NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-10-23
Research Workspace
Put UL beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Household Products is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — annual revenue near $51.6 billion: Direct metric needs a verified mapping.
View ThesisModerate volatility — typically moves about 1% a day.
View RiskUL’s case rests on emerging-market growth, especially its India strategy. Revenue growth direction and the latest earnings result are unavailable. The desk records no earnings release, so recent growth cannot be verified. The desk has no valuation multiple or peer comparison for UL. A 40% next-quarter miss probability makes execution a specific risk. The desk lacks a valuation read, so the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-23. UL is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 6 analysts currently covering UL (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare UL with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| UL Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-23. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Household Products — fair value, gap to price, and forward P/E.
Compare the value case
Put UL next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Price target cut indicates lower earnings expectations.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-23. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.

Recall damages brand trust and sales potential.

New capacity supports product expansion in a key market.

New capacity supports growth and product availability.

Competition review may hinder strategic partnerships.

Accusations could undermine management's credibility and leadership.

UK scrutiny may hinder Unilever's food deal progress.

Competition scrutiny may hinder strategic objectives.
